Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 2.23
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Conduit Pharmaceuticals Limited operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. The company was incorporated in 2022 and is based in Grand Cayman, Cayman Islands.Conduit Pharmaceuticals Limited operates as a subsidiary of Corvus Capital Limited.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is underpriced on P/FCF.
Data is available to registered users only
Buy
Sell